PDCD1 and hepatocellular carcinoma: Recent advances in immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death-ligand 1 (PD-L1), and programmed cell death protein 1 (PD-1), have revolutionized HCC treatment.